rTMS-induced Cumulative Pattern of sBDNF in Chronic Schizophrenia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2011 by Jeonbuk Provincial Maeumsarang Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
HWANG TAEYOUNG, Jeonbuk Provincial Maeumsarang Hospital
ClinicalTrials.gov Identifier:
NCT01427088
First received: August 28, 2011
Last updated: August 30, 2011
Last verified: August 2011
  Purpose

This study aims at investigating the neuroplastic potential and the possible factors affecting rehabilitation in chronic schizophrenia patients on stable medication, by investigating the cumulative pattern of serum BDNF representing the neuroplasticity in the brain, through quantitative stimulus such as rTMS.


Condition Intervention
Schizophrenia
Device: CR Technology, TAMAS for rTMS

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science

Resource links provided by NLM:


Further study details as provided by Jeonbuk Provincial Maeumsarang Hospital:

Primary Outcome Measures:
  • change from baseline of serum BDNF concentration [ Time Frame: baseline-1 week-2 week-4 week ] [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: August 2011
Estimated Study Completion Date: November 2011
Estimated Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: repetitive Transcranial Magnetic Stimulation
quantitative stimulation of rTMS, Left DLPFC, 20HZ, 100% of MEP
Device: CR Technology, TAMAS for rTMS
rTMS, lef DLPFC, 20Hz, 100% of MEP, 2weeks

  Eligibility

Ages Eligible for Study:   25 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • duration of illness over 10 years
  • on stable medication, antipsychotics
  • no change on medication within at least 2 weeks
  • Diagnosis of Schizophrenia according to DSM-IV-TR

Exclusion Criteria:

  • left or both-handedness
  • anticonvulsant use
  • lorazepam equivalent over 3 mg
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01427088

Contacts
Contact: TAEYOUNG HWANG, M.D., M.P.H. +82-63-240-2282 tyhwang73@naver.com

Locations
Korea, Republic of
Jeonbuk Provincial Maeumsarang Hospital Recruiting
Wanju, Jeonbuk, Korea, Republic of, 565844
Contact: TAEYOUNG HWANG, M.D., M.P.H.       tyhwang73@naver.com   
Principal Investigator: TAEYOUNG HWANG, M.D., M.P.H.         
Sponsors and Collaborators
Jeonbuk Provincial Maeumsarang Hospital
Investigators
Principal Investigator: TAEYOUNG HWANG, M.D., M.P.H. Jeonbuk Provincial Maeumsarang Hospital
  More Information

No publications provided

Responsible Party: HWANG TAEYOUNG, Director, Insan Research Center for Psychiatry, Jeonbuk Provincial Maeumsarang Hospital
ClinicalTrials.gov Identifier: NCT01427088     History of Changes
Other Study ID Numbers: rTMS-sBDNF-SPR-2011
Study First Received: August 28, 2011
Last Updated: August 30, 2011
Health Authority: Korea: Institutional Review Board

Keywords provided by Jeonbuk Provincial Maeumsarang Hospital:
rTMS-induced cumulative pattern of sBDNF

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders

ClinicalTrials.gov processed this record on August 21, 2014